Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
The efficacy of Hebelys® once again demonstrated and promoted in the International Journal of Cosmetic Science New in vitro and clinical efficacy data have been published;Sphingomonas hydrophobicum...
-
L’efficacité d’Hebelys® à nouveau démontrée et promue dans l’International Journal of Cosmetic Science De nouvelles données d’efficacité in vitro et cliniques ont été publiées ;L'extrait de...
-
DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019 Major Steven Zumbrun (USAMRIID1, U.S. Department of Defense) presented data on the in vitro assessment of...
-
L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019 Le Major Steven Zumbrun (USAMRIID1, Département de la Défense des Etats-Unis) a présenté la...
-
The tests aimed at validating the dosage required have confirmed a very good efficacy of the ingredientThe teams are working to develop a formulation that meets regulatory and industrial requirements...
-
DEINOVE & Dow sign a collaboration agreement for the development of a new cosmetic active ingredient
DEINOVE & Dow sign a collaboration agreement for the development of a new cosmetic active ingredient Dow has selected an extract belonging to the DEINOVE proprietary strains’ bank to launch a new...
-
DEINOVE & Dow signent un accord de collaboration pour le développement d’un nouvel actif cosmétique Dow a sélectionné un extrait issu de la collection bactérienne propriétaire de DEINOVE pour...
-
Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approachThis appointment underlines the importance of the bioactive...
-
L’USAMRIID (United States Army Medical Research Institute of Infectious Diseases) evaluated DNV3681 against Bacillus anthracis that triggers anthrax and Francisella tularensis that triggers tularemia...
-
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837 Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic...